EMA: Response to TB CAB letter

EMA's response to TB CAB letter regarding conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783).

/

Download the letter from here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:


News

By European Medicines Agency

Published: July 8, 2012, 10:29 a.m.

Last updated: July 8, 2012, 10:32 a.m.

Tags: None

Print Share